perampanel sold brand name fycompa antiepileptic medication developed eisai co used addition drugs treat partial seizures generalized tonicclonic seizures people older twelve first approved optimal role treatment epilepsy relative drugs first antiepileptic drug class selective noncompetitive antagonist ampa drug label black box warning drug may cause serious psychiatric behavioral changes may cause homicidal suicidal side effects included dizziness somnolence vertigo aggression anger loss coordination blurred vision irritability slurred perampanel reduced effectiveness levonorgestrel oral contraceptives women may get pregnant take studies animals show may harm perampanel liable abused high doses produced euphoria responses similar designated schedule iii controlled substance drug enforcement august perampanel studied development discontinued migraine multiple sclerosis neuropathic pain parkinsons perampanel used addition drugs treat partial seizures generalized tonicclonic seizures people older twelve review found effective indications due newness drug unable describe optimal role treatment epilepsy relative review probability added benefit perampanel standard care unable come conclusions trial conducted eisai compared perampanel drug within standard care based animal data perampanel may cause fetal recommended women childbearing age taking people severe liver impairment severe kidney disease including dialysis take perampanels label black box warning noting people taking drug undergone serious psychiatric behavioral changes events occurred people history issues well people history psychiatric changes included mood changes like euphoric mood anger irritability aggression belligerence agitation anxiety well psychosis acute psychosis hallucinations delusions paranoia delirium delirium confusional state disorientation memory impairment behavioral changes included physical assault homicidal ideation andor serious side effects include suicidal thoughts behavior like antiepileptic drugs dizziness gait disturbance somnolence fatigue risk falls increased risk seizures drug quickly clinical trials dizziness somnolence vertigo aggression anger loss coordination blurred vision irritability slurred speech side effects commonly led people leave perampanel liable abused high doses produced euphoria responses similar ketamine although subjects liked less experienced negatively ketamine produced dissociative effects similar designated schedule iii controlled substance drug enforcement study dependence rats found withdrawal symptoms drug removed dependence humans wasnt studied well enough make generalizations april limited experience perampanel reduced effectiveness levonorgestrel oral contraceptives antieptilectic drugs induce cytochrome including carbamazepine phenytoin oxcarbazepine decrease effectiveness perampanel use perampanel strong inducers like rifampin st johns wort recommended use perampanel cns depressants like alcohol may increase effect cns perampanel selective noncompetitive antagonist ampa receptors major subtype ionotropic glutamate first drug class approved wholecell voltage clamp studies demonstrated perampanel negative allosteric ampa receptor perampanel caused slow μm concentrationdependent inhibition ampa receptor currents rates block unblock ampa receptor currents respectively perampanel affect nmda receptor currents extent block μm similar agonist concentrations demonstrating noncompetitive blocking action parampanel affect ampa receptor desensitization ratio peak late response rapid application perampanel selective negative allosteric ampa receptor antagonist highaffinity slow blocking kinetics usedependent perampanel prolonged terminal halflife humans approximately hours drug bound plasma protein primary route metabolism induce enzymes dose excreted feces urine less dose excreted unchanged perampanels chemical formula bipyridine core structure sets apart ampa receptor tablets contain lactose monohydrate low substituted hydroxypropyl cellulose povidone microcrystalline cellulose magnesium stearate hypromellose polyethylene glycol talc titanium dioxide addition api oral suspension contains sorbitol microcrystalline cellulose carboxymethylcellulose sodium poloxamer simethicone citric acid sodium benzoate purified water addition approved marketing brand name fycompa european medicines agency ema july july approved adjunct treatment partialonset seizures without secondarily generalised seizures people epilepsy older twelve years adjunct treatment primary generalised tonicclonic seizures people older twelve years idiopathic generalised first approved fda brand name october june uses european union one four new drugs epilepsy approved along clobazam onfi retigabine potiga eslicarbazepine acetate august perampanel studied development discontinued migraine multiple sclerosis neuropathic pain parkinsons httpsenwikipediaorgwikiperampanel